Phio Pharmaceuticals Corp.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Phio Pharmaceuticals Corp. is a clinical-stage biotechnology firm focused on advancing immuno-oncology therapies within the United States. The company’s foundation rests upon its proprietary INTASYL™ platform, which engineers self-delivering RNAi compounds designed to silence genes that enable tumors to evade the body’s immune system. This innovative approach seeks to enhance the immune response in cancerous environments and is adaptable for both intratumoral and adoptive cell therapy applications. Among its pipeline candidates, PH-762 is an INTASYL compound engineered to diminish the expression of the PD-1 checkpoint protein, thereby activating immune cells to identify and eliminate cancer cells. This compound is currently undergoing Phase 1b clinical trials for various cutaneous malignancies, including advanced squamous cell carcinoma, melanoma, and Merkel cell carcinoma, and has recently shown encouraging safety and efficacy results in these studies. PH-762 is also being explored in conjunction with AgonOx Inc.'s "double positive" tumor-infiltrating lymphocyte technology to improve T cell-based cancer immunotherapies. Another key program, PH-894, targets the epigenetic protein BRD4 to influence gene expression in both immune and tumor cells, aiming to bolster the effectiveness of adoptive cell therapies. Additionally, PH-804 is under development to target the TIGIT immune receptor, enhancing the function of T cells and natural killer cells. The company is also investigating other INTASYL compounds, including one targeting CTLA-4, and has expanded its focus to include potential cosmeceutical applications through an exploratory collaboration. Phio Pharmaceuticals Corp. was originally established in 2011 as RXi Pharmaceuticals Corporation, later adopting its current name in November 2018 to reflect its dedicated pursuit of immuno-oncology treatments. The company maintains its headquarters in Marlborough, Massachusetts.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
Financial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO)
Head-To-Head Contrast: ProKidney (NASDAQ:PROK) & Phio Pharmaceuticals (NASDAQ:PHIO)
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement
Phio Pharmaceuticals (PHIO) Projected to Post Earnings on Monday
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update